lipid panel c-reactive protein profile and level in males and females It's Heart Health month! Our

Telaprevir as monotherapy had minimal activity against HCV-3, as noted by a mild decrease in HCV RNA levels (-0.54 log10 IU/L at day 15),[70] while boceprevir has been found to be slightly more active than telaprevir against HCV-3 in cell-based assays, and to decrease HCV RNA levels comparable to those observed with the same dose in HCV-1 treatment-experienced patients in a phase 1 study.[71] As we have advanced in HCV therapy, even second wave protease inhibitors simeprevir, asunaprevir, faldaprevir and danoprevir have demonstrated limited activity against HCV-3.[72] Advances in therapy The main mechanism of action of most DAAs is the inhibition of an enzyme (protease or polymerase),[73] although some inhibit the assembly of the replication complex (NS5A inhibitors) or target the host factors that the virus uses (cyclophilin inhibitors)[74] (Table 1)

[DOI] [PubMed] [Google Scholar] 178.Murdoch C, Unwin D, Cavan D, et al

( ): L-carnitine